intrahepatic cholangiocarcinoma (Cancer)
Information
- Disease name
- intrahepatic cholangiocarcinoma
- Disease ID
- DOID:4928
- Description
- "A cholangiocarcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree." [url:https\://www.dana-farber.org/intrahepatic-cholangiocarcinoma/]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| FOXL2 | 3 | 138,944,224 | 138,947,137 | 4 |
| MDC1 | 6 | 30,699,807 | 30,717,281 | 2 |
| TTK | 6 | 80,004,649 | 80,042,527 | 2 |
| SSBP2 | 5 | 81,412,804 | 81,751,097 | 2 |
| FLT4 | 5 | 180,601,506 | 180,649,600 | 2 |
| CBARP | 19 | 1,228,287 | 1,238,005 | 2 |
| EGFR | 7 | 55,019,017 | 55,211,628 | 2 |
| CEBPA | 19 | 33,299,934 | 33,302,534 | 2 |
| STK11 | 19 | 1,205,778 | 1,228,431 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05242822 | Active, not recruiting | Phase 1 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | April 18, 2022 | September 2026 |
| NCT05220722 | Active, not recruiting | Phase 1/Phase 2 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | March 2, 2022 | January 2025 |
| NCT02834013 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | January 30, 2017 | May 1, 2026 |
| NCT05239169 | Active, not recruiting | Phase 2 | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | May 23, 2022 | June 30, 2025 |
| NCT01862315 | Active, not recruiting | Phase 2 | Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) | May 2013 | May 2025 |
| NCT05781958 | Active, not recruiting | Phase 2 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | November 24, 2022 | December 1, 2024 |
| NCT03781934 | Active, not recruiting | Phase 1/Phase 2 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | September 5, 2018 | February 29, 2024 |
| NCT04526106 | Active, not recruiting | Phase 1/Phase 2 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | September 2, 2020 | October 2024 |
| NCT04087876 | Available | Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations | |||
| NCT03849469 | Completed | Phase 1 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | May 29, 2019 | February 16, 2023 |
| NCT01938729 | Completed | Phase 1 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma | September 5, 2013 | September 10, 2020 |
| NCT01954745 | Completed | Phase 2 | Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma | September 2013 | June 2016 |
| NCT01347333 | Completed | N/A | Stereotactic Body Radiotherapy for Liver Tumors | September 2008 | September 2016 |
| NCT02273739 | Completed | Phase 1/Phase 2 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | December 8, 2014 | June 3, 2016 |
| NCT05930119 | Completed | Phase 1 | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | March 17, 2023 | August 28, 2023 |
| NCT02762721 | Completed | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples | June 6, 2016 | April 6, 2017 | |
| NCT02807181 | Completed | Phase 2/Phase 3 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma | January 2017 | October 2022 |
| NCT01668134 | Completed | Phase 1 | Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma | December 16, 2009 | December 22, 2015 |
| NCT03230318 | Completed | Phase 2 | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma | September 28, 2017 | October 25, 2022 |
| NCT03251443 | Completed | Phase 2 | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | August 8, 2017 | May 8, 2019 |
| NCT03320980 | Completed | RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma | September 15, 2014 | October 1, 2017 | |
| NCT05489692 | Completed | HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma | September 1, 2017 | January 31, 2022 | |
| NCT01862276 | Completed | Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma | March 2013 | March 2014 | |
| NCT03796819 | Completed | N/A | Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma | January 10, 2019 | December 1, 2021 |
| NCT05342194 | Not yet recruiting | Phase 3 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | October 1, 2022 | May 31, 2027 |
| NCT06313554 | Not yet recruiting | N/A | Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma | May 20, 2024 | May 20, 2027 |
| NCT05009953 | Not yet recruiting | Phase 2 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | September 2021 | August 2024 |
| NCT05896956 | Not yet recruiting | The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases | July 1, 2023 | June 30, 2027 | |
| NCT05681949 | Not yet recruiting | N/A | Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards | November 2023 | July 2025 |
| NCT06406816 | Not yet recruiting | Early Phase 1 | Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection | May 2024 | May 2026 |
| NCT05422690 | Not yet recruiting | Phase 2 | The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer | May 15, 2024 | September 30, 2028 |
| NCT06134193 | Not yet recruiting | Phase 2 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | November 2023 | June 2025 |
| NCT06375642 | Not yet recruiting | Phase 2 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | May 10, 2024 | August 31, 2026 |
| NCT06417606 | Not yet recruiting | Phase 4 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | May 30, 2024 | May 30, 2025 |
| NCT05644743 | Not yet recruiting | Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma | January 2023 | December 2026 | |
| NCT05535647 | Not yet recruiting | Phase 2 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | September 25, 2022 | September 25, 2025 |
| NCT06208462 | Recruiting | Phase 2 | Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | March 25, 2024 | January 2027 |
| NCT02878473 | Recruiting | Phase 2 | Liver Transplantation for Early Intrahepatic Cholangiocarcinoma | April 5, 2018 | January 2029 |
| NCT02881554 | Recruiting | N/A | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery | December 21, 2016 | December 1, 2027 |
| NCT03633773 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | July 1, 2018 | December 31, 2024 |
| NCT04078230 | Recruiting | N/A | Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma | January 1, 2020 | December 31, 2027 |
| NCT04238637 | Recruiting | Phase 2 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | November 1, 2019 | December 2025 |
| NCT04299581 | Recruiting | Phase 2 | Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma | July 7, 2020 | May 10, 2024 |
| NCT04454905 | Recruiting | Phase 2 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | August 1, 2020 | July 1, 2025 |
| NCT05010681 | Recruiting | Phase 2 | Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer | August 24, 2021 | August 20, 2025 |
| NCT05174650 | Recruiting | Phase 2 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | April 20, 2022 | August 2026 |
| NCT05223816 | Recruiting | Phase 2 | An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | January 24, 2024 | December 31, 2025 |
| NCT05236699 | Recruiting | Phase 2 | A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC | February 1, 2022 | January 31, 2025 |
| NCT05251662 | Recruiting | Phase 2 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | January 13, 2022 | January 13, 2025 |
| NCT05285358 | Recruiting | Phase 1 | Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases | September 19, 2022 | October 11, 2028 |
| NCT05290116 | Recruiting | Phase 2 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | July 21, 2022 | September 1, 2023 |
| NCT05328167 | Recruiting | Phase 2 | Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment | December 14, 2021 | October 31, 2024 |
| NCT05400902 | Recruiting | Phase 2 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | May 31, 2023 | December 31, 2023 |
| NCT05557578 | Recruiting | Phase 2 | GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence | May 5, 2023 | December 2024 |
| NCT05565794 | Recruiting | Phase 2 | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | November 11, 2022 | November 2026 |
| NCT05672537 | Recruiting | Phase 2 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | January 20, 2023 | December 31, 2025 |
| NCT05678218 | Recruiting | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma | September 5, 2022 | February 1, 2026 | |
| NCT05712356 | Recruiting | Phase 2 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | August 24, 2023 | December 2025 |
| NCT05913661 | Recruiting | Phase 2 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | July 2023 | November 2024 |
| NCT06098547 | Recruiting | N/A | LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA) | January 15, 2024 | November 1, 2033 |
| NCT06101277 | Recruiting | N/A | Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) | October 5, 2023 | January 5, 2031 |
| NCT06140134 | Recruiting | Liver Transplantation in Intrahepatic Cholangiocarcinoma | December 15, 2023 | November 2029 | |
| NCT06160752 | Recruiting | Phase 1 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | November 22, 2023 | September 2027 |
| NCT06239532 | Recruiting | Phase 2 | HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma | September 27, 2022 | December 31, 2025 |
| NCT06290739 | Recruiting | A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma | February 7, 2024 | March 27, 2024 | |
| NCT06296563 | Recruiting | Phase 2 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | March 1, 2024 | March 1, 2029 |
| NCT06298968 | Recruiting | Phase 2 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | February 25, 2024 | February 25, 2027 |
| NCT06313203 | Recruiting | Phase 2 | HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) | February 13, 2024 | January 2034 |
| NCT06335927 | Recruiting | Phase 2 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | May 11, 2023 | May 10, 2026 |
| NCT06342414 | Recruiting | An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer | March 15, 2024 | March 15, 2025 | |
| NCT06370663 | Recruiting | Phase 2 | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC | April 1, 2024 | April 1, 2026 |
| NCT06375915 | Recruiting | Phase 2 | Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy | May 1, 2024 | January 2026 |
| NCT04556214 | Recruiting | N/A | Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial) | June 1, 2020 | May 31, 2035 |
| NCT04561453 | Recruiting | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | July 8, 2020 | July 1, 2025 | |
| NCT04669496 | Recruiting | Phase 2/Phase 3 | Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | January 20, 2021 | December 2024 |
| NCT04684862 | Recruiting | N/A | Infusion System for Hepatic Cancer | February 8, 2021 | July 2029 |
| NCT04891289 | Recruiting | Phase 2 | Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | May 7, 2021 | May 2025 |
| NCT04954781 | Recruiting | Phase 2 | TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma | July 14, 2021 | July 15, 2025 |
| NCT04961970 | Recruiting | Phase 3 | HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC | July 9, 2021 | July 9, 2025 |
| NCT05010668 | Recruiting | Phase 2 | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | August 24, 2021 | August 16, 2024 |
| NCT03779100 | Suspended | Phase 2 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | December 17, 2018 | December 31, 2019 |
| NCT02415036 | Terminated | Phase 2 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | June 2014 | December 2018 |
| NCT02254681 | Terminated | Phase 2 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | September 2014 | September 2016 |
| NCT02526771 | Unknown status | N/A | Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma | August 2015 | December 2017 |
| NCT02512692 | Unknown status | N/A | 90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma | July 21, 2015 | August 31, 2022 |
| NCT03345303 | Unknown status | Phase 3 | Bortezomib in Intrahepatic Cholangiocellular Carcinoma | January 2017 | December 2022 |
| NCT05327907 | Unknown status | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma | November 22, 2020 | May 22, 2023 | |
| NCT03086993 | Unknown status | Phase 2/Phase 3 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | April 10, 2018 | May 2023 |
| NCT04961788 | Unknown status | Phase 2 | Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma | July 1, 2021 | December 31, 2022 |
| NCT01914289 | Unknown status | N/A | Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients | January 2011 | April 2016 |
| NCT02238613 | Unknown status | N/A | Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer | August 2014 | June 2017 |
| NCT02184871 | Unknown status | Next Generation Sequencing in Intrahepatic Cholangiocarcinoma | May 2014 | May 2017 | |
| NCT03771846 | Unknown status | Phase 3 | HAIC Versus Systemic Chemotherapy for Unresectable ICC | August 1, 2018 | August 1, 2022 |
| NCT04295317 | Unknown status | Phase 2 | PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery | August 1, 2020 | February 28, 2024 |
| NCT01917370 | Unknown status | VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway | October 2012 | December 2014 | |
| NCT02588755 | Unknown status | N/A | TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection | December 2015 | December 2017 |
| NCT05240040 | Unknown status | Treat Primary and Metastatic Liver Tumors | April 26, 2016 | May 2022 | |
| NCT03521219 | Unknown status | Phase 2 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | February 7, 2018 | November 2019 |
| NCT05247996 | Unknown status | N/A | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | March 1, 2022 | December 31, 2023 |
| NCT04834674 | Unknown status | Phase 2 | DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma | May 1, 2021 | April 30, 2024 |
| NCT05019677 | Withdrawn | Phase 2 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | September 1, 2021 | December 1, 2024 |
| NCT04546828 | Withdrawn | Phase 2 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea | February 1, 2021 | August 18, 2021 |
| NCT04479904 | Withdrawn | Phase 2 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | August 10, 2020 | February 10, 2022 |
| NCT03081039 | Withdrawn | Phase 3 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma | August 21, 2017 | December 31, 2022 |
| NCT04511793 | Withdrawn | N/A | Hepatic Artery Infusion (HAI) Program at Duke University | December 11, 2020 | December 31, 2022 |
| NCT03801499 | Withdrawn | Phase 2 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | September 1, 2018 | December 2019 |
| NCT01775280 | Withdrawn | Phase 2 | Response of Hepatic Tumors to Radioembolization | October 2012 | October 2015 |
| NCT05292443 | Withdrawn | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer | December 20, 2021 | March 17, 2023 |
- Disase is a (Disease Ontology)
- DOID:4947
- Cross Reference ID (Disease Ontology)
- GARD:6042
- Cross Reference ID (Disease Ontology)
- ICD10CM:C22.1
- Cross Reference ID (Disease Ontology)
- MESH:D018281
- Cross Reference ID (Disease Ontology)
- NCI:C35417
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:1260050006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0345905
- Exact Synonym (Disease Ontology)
- Intrahepatic bile duct carcinoma
- Exact Synonym (Disease Ontology)
- peripheral Cholangiocarcinoma